Supplementary Materials

The PDF file includes:

  • Fig. S1. Analysis of antigen binding.
  • Fig. S2. TNF concentrations measured with the drug-tolerant competition ELISA.
  • Fig. S3. Development of a TNF-adalimumab complex ELISA.
  • Fig. S4. Adalimumab-TNF complexes.
  • Fig. S5. Correlation between TNF and adalimumab concentrations.
  • Fig. S6. TNF concentrations at week 52 and at steady state in relation with clinical response.
  • Fig. S7. Validation of the relation between TNF concentrations at week 4 and clinical response.
  • Fig. S8. Different adalimumab cutoff concentrations did not affect the relation between TNF concentrations at week 4 and clinical response.
  • Fig. S9. TNF concentrations at week 4 in relation with baseline methotrexate use.
  • Fig. S10. Adalimumab concentrations and ADAs in healthy volunteers.
  • Table S1. Demographics of validation cohort.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: